Sucralfate is NOT recommended for chronic gastritis
Based on the strongest available evidence, sucralfate should not be prescribed for chronic gastritis in routine clinical practice. While older research studies from the late 1980s and early 1990s showed some benefit, the most recent and highest-quality guideline evidence explicitly recommends against oral sucralfate for gastrointestinal mucosal injury 1.
Why Sucralfate Should Not Be Used
The 2015 ESMO Clinical Practice Guidelines, based on MASCC/ISOO recommendations, strongly recommend against systemic sucralfate administered orally for treating gastrointestinal mucositis (Level I evidence) 1. This recommendation applies to patients receiving radiation therapy for solid tumors and extends to general gastrointestinal mucosal conditions.
The evidence shows that oral sucralfate:
- Has strong evidence indicating lack of effectiveness for GI mucosal injury 1
- May actually worsen some GI symptoms rather than improve them 2
- Has been consistently shown ineffective in multiple high-quality trials 2
The Exception: Sucralfate Enemas for Specific Radiation Injury
The only clinical scenario where sucralfate has guideline support is as enemas (not oral) for chronic radiation-induced proctitis with rectal bleeding 3. This is a completely different indication and route of administration:
Sucralfate enema protocol (for radiation proctitis only):
- 2 g sucralfate suspension mixed with 30-50 mL tap water
- Administered rectally via soft Foley catheter
- Patient rolls 360 degrees to coat rectal surface
- Retain for 20 minutes minimum
- Initially twice daily, then once daily for maintenance
- Bleeding likely recurs when stopped 3
What the Research Actually Shows for Chronic Gastritis
While older studies from 1989-1994 suggested sucralfate might improve endoscopic and histologic features of chronic gastritis 4, 5, 6, these findings have not translated into guideline recommendations. The most recent 2026 study 7 showed benefit when sucralfate was added to H. pylori eradication therapy, but this was for H. pylori-positive gastritis specifically, not chronic gastritis in general.
Critical limitation: These studies focused on endoscopic appearance and histology, not on the outcomes that matter most—mortality, quality of life, and long-term morbidity. The guideline panels reviewed this evidence and still recommended against oral sucralfate use.
What Should You Prescribe Instead?
For chronic gastritis management:
First-line approach:
- Proton pump inhibitors (PPIs) are the preferred agents for gastric mucosal protection 8
- Standard once-daily dosing (e.g., omeprazole 20-40 mg, pantoprazole 40 mg, esomeprazole 40 mg)
- PPIs have superior evidence for reducing gastric injury compared to H2-receptor antagonists 8, 9
If H. pylori-positive:
- Standard quadruple eradication therapy is the priority
- PPI-based regimens are standard of care
Alternative considerations:
- H2-receptor antagonists (famotidine 40 mg daily, ranitidine if available) are second-line options 9
- Address underlying causes (NSAIDs, alcohol, smoking)
Important Caveats
Do not confuse indications:
- Sucralfate has FDA approval for duodenal ulcer treatment (1 g four times daily, 1 hour before meals and at bedtime) 10
- This is NOT the same as chronic gastritis
- Even for duodenal ulcers, PPIs are now preferred first-line therapy
Drug interactions to avoid:
- Sucralfate binds many medications in the GI tract, reducing their absorption 10
- Affects: fluoroquinolones, levothyroxine, phenytoin, digoxin, warfarin, ketoconazole
- Must separate dosing by 2 hours if sucralfate is used for any reason
Renal impairment warning:
- Sucralfate contains aluminum, which accumulates in chronic kidney disease 10
- Can cause aluminum toxicity (encephalopathy, osteodystrophy) in dialysis patients
- Use with extreme caution or avoid entirely in CKD
Bottom Line
For chronic gastritis, prescribe a PPI, not sucralfate. The evidence is clear that oral sucralfate lacks effectiveness for this indication and may cause harm through drug interactions and aluminum accumulation. Reserve sucralfate enemas exclusively for radiation-induced proctitis with bleeding, where they have specific guideline support as a temporizing measure.